Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRD

With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates and MRD negativity in IDH1-mutated AML, offering a promising treatment option for these patients.

EP: 1.Overview of KOMET-007: Ziftomenib Use in NPM-1m or KMT2A-r AML

EP: 2.CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3

Now Viewing

EP: 3.Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRD

Recent Videos